Evidence map›Paper›PMID 36481838›Full record

ArticleBone marrow transplantation2023

Tixagevimab/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases.

Armelle Otiniano, Zoe van de Wyngaert, Eolia Brissot, Rémy Dulery, Joel Gozlan, Anne Daguenel, Yasmine Abi Aad, Laure Ricard, Nicolas Stocker, Anne Banet and 9 more

Open access · bronzeAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone marrow transplantation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Armelle OtinianoService d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, INSERM UMRs 938, Paris, France.
Zoe van de WyngaertService d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, INSERM UMRs 938, Paris, France.
Eolia BrissotService d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, INSERM UMRs 938, Paris, France.ORCID 0000-0003-4471-418X
Rémy DuleryService d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, INSERM UMRs 938, Paris, France.ORCID 0000-0002-5024-1713
Joel GozlanService de virologie, APHP, Hôpital Saint Antoine, Paris, France.
Anne DaguenelPharmacie, Hôpital Saint-Antoine, AP-HP, Paris, France.
Yasmine Abi AadSorbonne Université, IPLESP UMR-S1136, Service de maladies infectieuses et tropicales, Hôpital Saint Antoine, AP-HP, Paris, France.
Laure RicardService d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, INSERM UMRs 938, Paris, France.
Nicolas StockerService d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, INSERM UMRs 938, Paris, France.ORCID 0000-0001-7316-5832
Anne BanetService d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, INSERM UMRs 938, Paris, France.
Agnes BonninService d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, INSERM UMRs 938, Paris, France.
Tamim AlsulimanService d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, INSERM UMRs 938, Paris, France.
Zora MarjanovicService d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, INSERM UMRs 938, Paris, France.
Aurélie SchnurigerService de virologie, APHP, Hôpital Saint Antoine, Paris, France.
Paul CoppoService d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, INSERM UMRs 938, Paris, France.
Ollivier LegrandService d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, INSERM UMRs 938, Paris, France.
Karine LacombeSorbonne Université, IPLESP UMR-S1136, Service de maladies infectieuses et tropicales, Hôpital Saint Antoine, AP-HP, Paris, France.
Mohamad MohtyService d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, INSERM UMRs 938, Paris, France.ORCID 0000-0002-7264-808X
Florent MalardService d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, INSERM UMRs 938, Paris, France. florent.malard@inserm.fr.ORCID 0000-0002-3474-0002
Inserm · FRSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Hematologic DiseasesAntibodies, MonoclonalHumansSARS-CoV-2Antibodies, Monoclonalcilgavimabtixagevimab

Identifiers

PMID36481838
PMCPMC9734768
OpenAlexW4311288371

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.